Radius Health Inc (NASDAQ:RDUS) Expected to Post Quarterly Sales of $40.49 Million
Equities research analysts expect Radius Health Inc (NASDAQ:RDUS) to announce $40.49 million in sales for the current quarter, Zacks reports. Four analysts have made estimates for Radius Health’s earnings, with estimates ranging from $37.59 million to $43.00 million. Radius Health reported sales of $22.63 million during the same quarter last year, which would suggest a positive year over year growth rate of 78.9%. The company is expected to issue its next earnings report after the market closes on Wednesday, August 7th.
According to Zacks, analysts expect that Radius Health will report full-year sales of $170.45 million for the current financial year, with estimates ranging from $167.05 million to $174.74 million. For the next year, analysts expect that the company will post sales of $236.56 million, with estimates ranging from $205.71 million to $256.03 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Radius Health.
Radius Health (NASDAQ:RDUS) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.01. Radius Health had a negative net margin of 176.84% and a negative return on equity of 233.12%. The business had revenue of $29.84 million for the quarter, compared to analyst estimates of $35.35 million. During the same period last year, the business posted ($1.11) EPS. Radius Health’s revenue was up 105.1% compared to the same quarter last year.
In related news, VP Joseph Francis Kelly purchased 2,500 shares of the firm’s stock in a transaction on Friday, June 7th. The shares were bought at an average cost of $21.81 per share, for a total transaction of $54,525.00. Following the transaction, the vice president now directly owns 7,500 shares of the company’s stock, valued at approximately $163,575. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Anthony Rosenberg sold 1,584 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $24.60, for a total transaction of $38,966.40. Following the completion of the sale, the director now owns 8,716 shares in the company, valued at $214,413.60. The disclosure for this sale can be found here. Company insiders own 4.00% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. California Public Employees Retirement System raised its stake in Radius Health by 25.3% in the fourth quarter. California Public Employees Retirement System now owns 73,700 shares of the biopharmaceutical company’s stock valued at $1,215,000 after buying an additional 14,900 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Radius Health by 8.6% during the fourth quarter. Geode Capital Management LLC now owns 457,063 shares of the biopharmaceutical company’s stock worth $7,536,000 after purchasing an additional 36,093 shares in the last quarter. Two Sigma Investments LP acquired a new stake in shares of Radius Health during the fourth quarter worth about $981,000. Paloma Partners Management Co acquired a new stake in shares of Radius Health during the fourth quarter worth about $218,000. Finally, Metropolitan Life Insurance Co. NY increased its position in shares of Radius Health by 395.0% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 13,549 shares of the biopharmaceutical company’s stock worth $223,000 after purchasing an additional 10,812 shares in the last quarter.
NASDAQ:RDUS opened at $21.88 on Friday. Radius Health has a 1 year low of $12.81 and a 1 year high of $25.40. The firm has a fifty day moving average price of $23.00. The company has a quick ratio of 5.04, a current ratio of 5.16 and a debt-to-equity ratio of 6.75. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -4.48 and a beta of 1.06.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Featured Article: Overbought
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.